alexa Intratumoral Heterogeneity And Identification Of Tumor Initiating Cells (tic) For Cancer Vaccination
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Vaccines & Vaccination
July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Saroj Basak
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.016
Abstract
C ancer vaccination strategies require vaccination against cancer antigens that are expressed on tumor cells. However, with the recognition that most cancer consists of heterogeneous tumor cells that expresses different markers and antigens during cancer progression it has become imperative to identify the tumor cells that are responsible for cancer initiation and progression and target these cells for effective vaccination against cancer. These cells are also known as Tumor Initiating Cells (TIC) or Cancer Stem Cells (CSC) and our laboratory is involved in identifying these cells and developing immunotherapy strategy against them for cancer vaccination. Our studies with advance stage lung cancer bio-specimens from Malignant Pleural Effusion (MPE) patients have indicated that tumor cell heterogeneity exists in terms of cell surface markers expression (CD44, CD166, cMET, MDR1, uPAR) and molecular markers associated with TIC/CSC (BMI-1, hTERT, EZH2, OCT-4). These primary tumor cells express the CD44 surface marker on most of the tumor cells (75-95%). However, the intensity of CD44 surface marker expression varies and cells can be identified and sorted as high CD44 (CD44 hi ) and low CD44 (CD44 lo ) expressing cells. The CD44 hi cells are more efficient in forming soft agar colonies (1.5-2.5 times), are more tumorigenic in NOD/SCID (IL-2 null ) mice and express high level of specific TIC/CSC molecular markers than CD44 lo cells. The CD44 hi cells have significantly lower miR-34a than CD44 lo cells and introduction of miR-34a resulted in 80-95% reduction of soft agar colonies. The cells were also evaluated for adenoviral entry receptors (CAR, avb3, avb5) for consideration of targeted gene-therapy. Remarkably, over 80% of the CD44 cells co-express CAR and av5, but not av3. These cells undergo apoptosis by UV radiation and can also be efficiently loaded on human dendritic cells (DC) for efficient delivery to the immune system.
Biography
Saroj Basak is involved with vaccination research and translational cancer therapy at UCLA. His research works involve development of immunotherapy and gene therapy strategies against cancer using viral vectors (adenovirus, helper-dependent adenovirus, lentivirus) and dendritic cells mediated immunotherapy. He has numerous publications and has received several grants for improvement of vaccination strategies for cancer. He is an expert in pre clinical studies; animal model development using primary cancer cells, dendritic cells mediated vaccination and therapy. Currently his laboratory is involved with identifying and characterizing cancer initiating cells and development of targeted therapy and vaccination strategies against these cells. His laboratory is also involved in evaluating the effect of biologics and natural products in overcoming drug resistance in cancer
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]csonline.com

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords